Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05872295 · ClinicalTrials.gov registry record · Phase 1
IKS014 in Advanced Solid Tumors That Express HER2
A Phase 1 study of Breast Cancer and Gastric Cancer, sponsored by Iksuda Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 12
- Study locations
NCT05872295: Recruiting Phase 1 study of Breast Cancer and Gastric Cancer, sponsored by Iksuda Therapeutics.
NCT05872295 is a Phase 1 study of Breast Cancer and Gastric Cancer that is actively recruiting participants, run by Iksuda Therapeutics. The registered enrollment target is 165 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05872295, a Phase 1 study of Breast Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Iksuda Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Primary Outcome
Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics
Conditions Studied
Interventions
- DRUG IKS014
Study Locations (12)
New South Wales
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit - Concord
- Macquarie University - Sydney
- Westmead Hospital - Westmead
Other
- Auckland City Hospital - Auckland
- National Cancer Centre Singapore - Singapore
- Tan Tock Seng Hospital - Singapore
Victoria
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG) - Frankston
- Alfred Health - Melbourne
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Massachusetts
- Dana Farber Cancer Institute - Boston
Tennessee
- Tennessee Oncology - Nashville
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT05872295 shows while recruiting
NCT05872295 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IKS014 is the first listed.
NCT05872295 lists 12 locations in 7 states (New South Wales, Other, Victoria).
Frequently Asked Questions
What is clinical trial NCT05872295 about?
NCT05872295 is a clinical study titled "IKS014 in Advanced Solid Tumors That Express HER2". This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
What is the current status of trial NCT05872295?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2023-09-14. Estimated completion is 2027-09.
What conditions does trial NCT05872295 study?
This clinical trial studies the following conditions: Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT05872295?
The interventions under investigation include: IKS014 (DRUG).
Who is sponsoring clinical trial NCT05872295?
This trial is sponsored by Iksuda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05872295 being conducted?
This trial has 12 study locations across California, Massachusetts, Tennessee, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05872295's enrollment target sits among peer trials
165 426th of 1224 higher than 797 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
- NCT04458584 · 165 participants
Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI